Senior Leadership

高级领导层 Stanton L.Gerson，医学博士，Case综合癌症中心(Case CCC)主任 Gerson博士被任命为病例综合癌症中心主任兼副院长 于2004年9月发表于肿瘤学杂志。 资格：Gerson博士是造血和免疫细胞生物学的项目负责人 1992-2004年，临床研究副主任，1995-2004年。他是 1993年晋升为终身教授，#年被任命为希弗里克血液肿瘤学教授 1997年，当选为美国医师协会会员。Gerson博士成为了 1995年成立血液科-肿瘤科。Gerson博士为NIH的同行提供了广泛的服务 自1989年以来担任实验治疗学研究部分特别审查员的审查过程 1997-2002年(2000-2002年担任主席)；2001-2005年突袭方案SAB；小组委员会D 计划项目研究部分(2004-)；以及2005年NCI-RAID计划的NCI外部审查。 他目前是NCI癌症中心主任工作组早期检测小组的主席 由医学博士John Mendelsohn担任主席，就2015年的倡议向NCI提供指导。Gerson医生已经 发表了175多篇同行评议论文，并参与编辑了2篇文本，《癌症的基因治疗》(1999,2002) 和临床血液学(2005)。Gerson博士在福克斯的外部咨询委员会任职 大通综合癌症中心、金摩尔·约翰霍普金斯综合癌症中心，以及 爱荷华州综合癌症中心。他花了50%的时间管理综合 癌症中心，35%致力于他的研究，10%努力管理爱尔兰癌症中心，5% 在病人护理上的努力。 研究成就：Gerson博士的研究集中在三个相关领域：STEM 以细胞生物学、DNA修复和药物开发相关的DNA修复为靶点。他一直是 自1984年以来一直由美国国立卫生研究院资助。这些活动的详细信息在概述中介绍， 第6.7条。 权限：作为主任，Gerson博士有权批准和审查成员资格，包括 Case CCC的高级和计划负责人。他可以对中心进行初步任命，并且 利用癌症中心的资源，促进招聘到凯斯学院的许多主要部门 医学和克利夫兰大学医院的临床科室。他有责任成为一名 凯斯医学院和克利夫兰大学医院的系主任。他也 积极参与勒纳研究所和陶西格癌症研究所的研究管理活动 通过直接参加他们的搜索委员会和通过高级领导委员会 癌症中心，其中包括勒纳研究所副主任和 陶西格癌症中心副主任，在制定成员和 克利夫兰诊所的项目。这一点在联合机构领导信中得到了进一步定义。Dr。 Gerson对Case CCC的所有共享资源拥有财政和行政权力，面积为47,000平方英尺 沃尔斯坦大楼的研究空间，生物医学研究大楼的共享资源空间和 案例医学院西尔斯塔楼，世界上的研究行政空间 克利夫兰大学医院大楼，临床肿瘤学空间和服务(医疗、放射 和外科)克利夫兰大学医院和爱尔兰大学癌症中心网站 医院卫生系统。此外，Gerson博士还在克利夫兰指导委员会任职 由CASE提交的临床与翻译科学奖(CTSA)申请，包括附属的 医院，2006年3月。Gerson博士召集了该案件的外部和内部咨询委员会 CCC并根据他们的建议，就计划、共享资源和战略规划做出决定 中心。

SENIOR LEADERSHIP Stanton L. Gerson, MD, Director, Case Comprehensive Cancer Center (Case CCC) Dr. Gerson was named Director of the Case Comprehensive Cancer Center and Associate Dean for Oncology in September, 2004. Qualifications: Dr. Gerson was Program Leader for the Hematopoietic and Immune Cell Biology Program from 1992-2004, and Associate Director for Clinical Research from 1995-2004. He was promoted to tenured Professor in 1993, was named the Shiverick Professor for Hematological Oncology in 1997, and elected to the American Association of Physicians in 1997. Dr. Gerson became the Chief of the Division of Hematology-Oncology in 1995. Dr. Gerson has provided extensive service to the NIH peer review process, serving as ad hoc reviewer since 1989, on the Experimental Therapeutics study section from 1997-2002 (Chair from 2000-2002); the RAID program SAB from 2001-2005; Subcommittee D for the Program Projects study section (2004-); and the NCI external review for the NCI-RAID program in 2005 . He currently chairs the Early Detection Subcommittee for the NCI Cancer Center Directors Working Group chaired by John Mendelsohn, MD, to provide guidance to the NCI on the 2015 initiative. Dr. Gerson has published over 175 peer-reviewed papers, and co-edited 2 texts, Gene Therapy of Cancer (1999, 2002) and Clinical Hematology (2005). Dr. Gerson serves on the External Advisory Committees for the Fox Chase Comprehensive Cancer Center, the Kimmel Johns Hopkins Comprehensive Cancer Center, and the Iowa Comprehensive Cancer Center. He spends 50% of his time administering the Comprehensive Cancer Center, 35% effort on his research, 10% effort administering the Ireland Cancer Center, and 5% effort on patient care. Research Accomplishments: Dr. Gerson's research has focused on three related areas: stem cell biology, DNA repair, and drug development related to DNA repair as a target. He has been continuously funded by the NIH since 1984. Details of these activities are described in the Overview, section 6.7. Authority: As Director, Dr. Gerson has authority to approve and review membership including Senior and Program Leaders to the Case CCC. He can make primary appointments to the Center, and with Cancer Center resources, facilitate recruitments to many primary departments of Case School of Medicine and to Clinical Departments of University Hospitals of Cleveland. He has the responsibilities of a Department Chair at both Case School of Medicine and University Hospitals of Cleveland. He also actively participates in research administrative activities at Lerner Research Institute and Taussig Cancer Center by participating directly on their search committees, and through the Senior Leadership Committee of the Cancer Center, which includes the Associate Director for the Lerner Research Institute and the Associate Director for the Taussig Cancer Center, in setting the cancer research priorities of members and programs of the Cleveland Clinic. This is further defined in the joint institutional leadership letter. Dr. Gerson has fiscal and administrative authority over all Shared Resources of the Case CCC, 47,000 sq ft of research space in the Wolstein Building, shared resource space in the Biomedical Research Building and Sears Tower Building of the Case School of Medicine, research administrative space in the Wearn Building of University Hospitals of Cleveland, the clinical oncology space and services (medical, radiation and surgical) of University Hospitals of Cleveland and the Ireland Cancer Center sites of University Hospital Health System. In addition, Dr. Gerson serves on the Steering Committee of the Cleveland Clinical & Translational Science Award (CTSA) application submitted by Case and including the affiliated hospitals in March 2006. Dr. Gerson convenes the External and Internal Advisory Boards of the Case CCC and with their advice, makes decisions on Programs, Shared Resources and strategic planning for the Center.